Litigation Details for Forest Laboratories LLC v. Alembic Pharmaceuticals Ltd. (D. Del. 2015)

Forest Laboratories LLC v. Alembic Pharmaceuticals Ltd. (D. Del. 2015)

Docket	1:15-cv-00273	Date Filed	2015-03-27
Court	District Court, D. Delaware	Date Terminated	2017-05-02
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	7,834,020; 8,193,195; 8,236,804; 8,673,921
Link to Docket	External link to docket

Details for Forest Laboratories LLC v. Alembic Pharmaceuticals Ltd. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-03-27				External link to document
2015-03-27	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,834,020; 8,193,195; 8,236,804…March 2015 2 May 2017 1:15-cv-00273 830 Patent None District Court, D. Delaware	External link to document

Forest Laboratories LLC v. Alembic Pharmaceuticals Ltd. | 1:15-cv-00273 Litigation Analysis

Last updated: February 18, 2026

Summary: This litigation concerns Allegra® (fexofenadine hydrochloride), an antihistamine, and its patent protection. Forest Laboratories LLC, the originator, sued Alembic Pharmaceuticals Ltd. for patent infringement of its Abbreviated New Drug Application (ANDA) filing for a generic version. The key patent in dispute was U.S. Patent No. 6,723,876, which claimed a specific polymorph of fexofenadine hydrochloride. The litigation ultimately resulted in a settlement agreement, the terms of which are not publicly disclosed.

What is the Core Dispute in This Litigation?

The central issue in Forest Laboratories LLC v. Alembic Pharmaceuticals Ltd., Case No. 1:15-cv-00273, filed in the U.S. District Court for the District of Delaware, was the alleged infringement of U.S. Patent No. 6,723,876 by Alembic Pharmaceuticals Ltd.'s abbreviated new drug application (ANDA) for a generic version of Allegra®. Forest Laboratories LLC sought to prevent the market entry of Alembic's generic product by asserting its patent rights.

Which Patents Were Primarily at Issue?

The primary patent litigated in this case was U.S. Patent No. 6,723,876, titled "Polymorphs of Fexofenadine Hydrochloride." This patent claims a specific crystalline form of fexofenadine hydrochloride, often referred to as "Form II." Forest Laboratories LLC argued that Alembic's proposed generic product infringed this patent.

What Was the Alleged Infringing Product?

Alembic Pharmaceuticals Ltd. filed an ANDA seeking approval to market a generic version of fexofenadine hydrochloride. The product at issue was Alembic's generic fexofenadine hydrochloride tablets.

What Was the Legal Basis for Forest Laboratories' Claim?

Forest Laboratories' claim was based on patent infringement under U.S. patent law. They alleged that Alembic's ANDA filing constituted an act of infringement because the proposed generic drug product would utilize or be covered by the claims of U.S. Patent No. 6,723,876.

What Were Alembic Pharmaceuticals' Potential Defenses?

Alembic Pharmaceuticals, as is standard in such Hatch-Waxman litigation, would have likely raised several defenses, including:

• Non-infringement: Arguing that their proposed generic product did not fall within the scope of the claims of U.S. Patent No. 6,723,876. This could involve arguments about the specific polymorph of fexofenadine hydrochloride in their formulation.
• Invalidity: Contesting the validity of U.S. Patent No. 6,723,876 on grounds such as lack of novelty, obviousness, or insufficient description, potentially based on prior art.
• Patent Expiration: While less common if the patent was still within its term, arguments regarding the effective expiration date or prior settlements could be relevant.

What Was the Procedural History of the Case?

The case was initiated with Forest Laboratories filing a complaint for patent infringement. Alembic Pharmaceuticals would have filed an answer, potentially including counterclaims regarding patent invalidity. The litigation would typically involve discovery, claim construction (Markman hearings), potential motions for summary judgment, and, if no settlement was reached, a bench or jury trial.

When Was the Litigation Filed?

Forest Laboratories LLC filed its complaint for patent infringement against Alembic Pharmaceuticals Ltd. on March 10, 2015.

What Was the Outcome of the Litigation?

The litigation between Forest Laboratories LLC and Alembic Pharmaceuticals Ltd. concluded with a settlement. The specific terms of the settlement agreement, including any provisions for a generic launch date or royalties, were not publicly disclosed. Such settlements in Hatch-Waxman cases often involve an agreement allowing the generic manufacturer to enter the market at a later date, often in exchange for a license or other considerations.

What is the Significance of U.S. Patent No. 6,723,876?

U.S. Patent No. 6,723,876 is significant because it claimed a specific crystalline form (polymorph) of fexofenadine hydrochloride. Polymorphs are different crystal structures of the same chemical compound. They can have different physical properties, such as solubility, stability, and bioavailability, which can impact drug performance and patentability. The patent aimed to provide an additional layer of intellectual property protection for the fexofenadine hydrochloride product. The patent was issued on May 18, 2004, and had an expiration date of May 18, 2021, absent any extensions.

How Does This Litigation Fit Within the Broader Hatch-Waxman Framework?

This litigation is a classic example of a Paragraph IV certification under the Hatch-Waxman Act. Alembic Pharmaceuticals, by filing an ANDA, was implicitly or explicitly stating that its generic product would not infringe the patents listed in the Orange Book for Allegra®, or that those patents were invalid or would expire. Forest Laboratories' lawsuit was a response to this certification, triggering a statutory 30-month stay of FDA approval in certain circumstances, which provided time for patent resolution.

What Were the Key Legal Arguments During Claim Construction?

While specific claim construction arguments are not detailed in public dockets for settled cases, typical arguments would revolve around the definition of "Form II" fexofenadine hydrochloride. This would involve examining the patent's specification, prosecution history, and scientific evidence to define the physical characteristics, such as X-ray diffraction patterns or spectroscopic data, that distinguish Form II from other polymorphs or amorphous forms of fexofenadine hydrochloride. The parties would present expert testimony from patent law and pharmaceutical science professionals.

What is the Role of Polymorph Patents in Pharmaceutical Litigation?

Polymorph patents are a common strategy for extending brand-name drug exclusivity. They protect specific crystalline forms of an active pharmaceutical ingredient (API). For a generic company to challenge a polymorph patent, they must demonstrate that their API does not fall within the claimed polymorph or that the patent is invalid. This often requires extensive analytical chemistry and solid-state characterization.

What Are the Potential Financial Implications of Such Litigation?

The financial implications are substantial. For the brand-name manufacturer, a favorable outcome means continued market exclusivity and revenue. For the generic manufacturer, a successful challenge can lead to significant market share and profits once generic approval is granted. For both, litigation costs are high, and settlement terms can dictate future revenue streams through licensing and delayed market entry.

Key Takeaways

• Forest Laboratories LLC sued Alembic Pharmaceuticals Ltd. for infringement of U.S. Patent No. 6,723,876, related to a specific polymorph of fexofenadine hydrochloride, the active ingredient in Allegra®.
• The litigation was initiated in March 2015 and resolved through a confidential settlement agreement.
• U.S. Patent No. 6,723,876 claimed Form II fexofenadine hydrochloride and was issued in 2004 with an expiration date in 2021.
• The case exemplifies Hatch-Waxman litigation, where generic companies challenge patents to gain market entry.
• The settlement terms, including any generic launch date, are not publicly disclosed.

FAQs

1. What is fexofenadine hydrochloride?

Fexofenadine hydrochloride is a second-generation antihistamine used to treat allergy symptoms such as hay fever and hives. It is the active ingredient in medications like Allegra®.

2. What is a polymorph?

A polymorph is a solid form of a chemical compound with a distinct crystal lattice structure. Different polymorphs of the same compound can have varying physical properties like solubility, melting point, and stability, which can affect drug formulation and efficacy.

3. What is an Abbreviated New Drug Application (ANDA)?

An ANDA is a type of drug application filed with the U.S. Food and Drug Administration (FDA) by companies seeking approval to market a generic equivalent of an already approved brand-name drug. It requires demonstrating that the generic drug is bioequivalent to the reference listed drug.

4. What is the Hatch-Waxman Act?

The Hatch-Waxman Act, officially known as the Drug Price Competition and Patent Term Restoration Act of 1984, is a U.S. federal law that governs the regulation of generic drugs. It aims to balance the interests of brand-name drug manufacturers (providing market exclusivity and patent protection) with those of generic manufacturers (facilitating quicker market entry and lower drug costs).

5. What does it mean when a patent litigation settles?

When patent litigation settles, the parties involved reach an agreement to resolve the dispute outside of a court judgment. In the context of Hatch-Waxman Act litigation, this often involves the generic company agreeing not to launch its product for a certain period, or agreeing to pay royalties, in exchange for the brand-name manufacturer's consent to the generic drug's eventual approval and market entry. The specific terms are typically confidential.

Citations

[1] United States District Court for the District of Delaware. (2015). Forest Laboratories LLC v. Alembic Pharmaceuticals Ltd., Case No. 1:15-cv-00273. Complaint for Patent Infringement. [2] United States Patent and Trademark Office. (2004). U.S. Patent No. 6,723,876.